Vandana Menon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Vandana Menon has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Mark J. Sarnak
Department of Medicine, Division of Nephrology, and †Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts; ‡Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio; §Division of Clinical Epidemiology, University of Utah, Salt Lake City, Utah; ‖National Institutes of Health, Bethesda, Maryland; and ¶Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota
4 shared publicationsAllan J. Collins
Department of Medicine, Division of Nephrology, and †Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts; ‡Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio; §Division of Clinical Epidemiology, University of Utah, Salt Lake City, Utah; ‖National Institutes of Health, Bethesda, Maryland; and ¶Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota
3 shared publicationsGerald J. Beck
Department of Medicine, Division of Nephrology, and †Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts; ‡Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio; §Division of Clinical Epidemiology, University of Utah, Salt Lake City, Utah; ‖National Institutes of Health, Bethesda, Maryland; and ¶Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota
3 shared publicationsJohn W. Kusek
Department of Medicine, Division of Nephrology, and †Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts; ‡Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio; §Division of Clinical Epidemiology, University of Utah, Salt Lake City, Utah; ‖National Institutes of Health, Bethesda, Maryland; and ¶Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota
3 shared publicationsTom Greene
Department of Medicine, Division of Nephrology, and †Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts; ‡Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio; §Division of Clinical Epidemiology, University of Utah, Salt Lake City, Utah; ‖National Institutes of Health, Bethesda, Maryland; and ¶Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota
3 shared publicationsXuelei Wang
Department of Medicine, Division of Nephrology, and †Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts; ‡Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio; §Division of Clinical Epidemiology, University of Utah, Salt Lake City, Utah; ‖National Institutes of Health, Bethesda, Maryland; and ¶Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota
3 shared publications
Latest Publications
- Open Access
- 1 June 2009
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 4 (6) , 1115-1120
Asymmetric Dimethylarginine and Mortality in Stages 3 to 4 Chronic Kidney Disease
Background and objectives: Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, reduces bioavailability of nitric oxide and induces endothelial dysfunction. This dimethylated amino acid accumulates in chronic kidney disease and may be involved in the pathophysiology of cardiovascular disease (CVD) in this population. Design, settings, participants, & methods: The Modification of Diet in Renal Disease Study was a randomized, controlled trial conducted between 1989 and 1993. We measured ADMA in frozen samples collected at baseline (n = 820) and obtained survival status, up to December 31, 2000, from the National Death Index. We examined the relationship of ADMA with prevalent CVD and performed multivariable Cox models to examine the relationship of ADMA with all-cause and CVD mortality. Results: Mean (SD) age was 52 (12) yr, GFR was 32 ± 12 ml/min per 1.73 m2, and ADMA was 0.70 ± 0.25 μmol/L. A 1-SD increase in ADMA was associated with a 31% increased odds of prevalent CVD in an adjusted logistic regression model. During the 10-yr follow-up period, 202 (25%) participants died of any cause, 122 (15%) from CVD, and 545 (66%) reached kidney failure. In multivariable Cox models, a 1-SD increase in ADMA was associated with a 9% increased risk for all-cause and 19% increased risk for CVD mortality. Conclusions: In this cohort of patients with predominantly nondiabetic, stages 3 to 4 chronic kidney disease, there was a strong association of ADMA with prevalent CVD and a modest association with all-cause and CVD mortality.
- 1 June 2009
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 4 (6) , 1115-1120
Open AccessAsymmetric Dimethylarginine and Mortality in Stages 3 to 4 Chronic Kidney Disease
Background and objectives: Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, reduces bioavailability of nitric oxide and induces endothelial dysfunction. This dimethylated amino acid accumulates in chronic kidney disease and may be involved in the pathophysiology of cardiovascular disease (CVD) in this population. Design, settings, participants, & methods: The Modification of Diet in Renal Disease Study was a randomized, controlled trial conducted between 1989 and 1993. We measured ADMA in frozen samples collected at baseline (n = 820) and obtained survival status, up to December 31, 2000, from the National Death Index. We examined the relationship of ADMA with prevalent CVD and performed multivariable Cox models to examine the relationship of ADMA with all-cause and CVD mortality. Results: Mean (SD) age was 52 (12) yr, GFR was 32 ± 12 ml/min per 1.73 m2, and ADMA was 0.70 ± 0.25 μmol/L. A 1-SD increase in ADMA was associated with a 31% increased odds of prevalent CVD in an adjusted logistic regression model. During the 10-yr follow-up period, 202 (25%) participants died of any cause, 122 (15%) from CVD, and 545 (66%) reached kidney failure. In multivariable Cox models, a 1-SD increase in ADMA was associated with a 9% increased risk for all-cause and 19% increased risk for CVD mortality. Conclusions: In this cohort of patients with predominantly nondiabetic, stages 3 to 4 chronic kidney disease, there was a strong association of ADMA with prevalent CVD and a modest association with all-cause and CVD mortality.
- 1 June 2008
- Published by Elsevier in Kidney International
- Vol. 73 (11) , 1310-1315
Long-term outcomes in nondiabetic chronic kidney disease
- 1 June 2008
- Published by Elsevier in Kidney International
- Vol. 73 (11) , 1310-1315
Long-term outcomes in nondiabetic chronic kidney disease
- 1 September 2007
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 50 (3) , 404-411
Body Mass Index and Mortality in CKD
- 1 September 2007
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 50 (3) , 404-411
Body Mass Index and Mortality in CKD
- 1 July 2007
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 23 (9) , 707-710
Homocysteine lowering and cardiovascular disease risk: Lost in translation
- 1 July 2007
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 23 (9) , 707-710
Homocysteine lowering and cardiovascular disease risk: Lost in translation
- Open Access
- 1 September 2006
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 17 (9) , 2599-2606
Adiponectin and Mortality in Patients with Chronic Kidney Disease
Adiponectin is presumed to possess antiatherogenic and cardioprotective properties. Limited data exist on the relationship between adiponectin and mortality in the earlier stages of chronic kidney disease. The Modification of Diet in Renal Disease study was a randomized, controlled trial that was conducted between 1989 and 1993. Adiponectin was measured in frozen samples that were obtained at baseline (N = 820). Survival status and cause of death, up to December 31, 2000, were obtained from the National Death Index. Multivariable Cox models were used to examine the relationship of adiponectin with all-cause and cardiovascular mortality. Mean ± SD age was 52 ± 12 yr, and mean ± SD glomerular filtration rate (GFR) rate was 33 ± 12 ml/min per 1.73 m2. Eighty-five percent of participants were white, and 60% were male. Mean ± SD adiponectin was 12.8 ± 8.0 μg/ml. Triglycerides, insulin resistance, glucose, body mass index, GFR, C-reactive protein, and albumin were inversely related and proteinuria and HDL cholesterol were directly related to adiponectin. During the 10-year follow-up period, 201 (25%) participants died of any cause, and 122 (15%) from cardiovascular disease. In multivariable adjusted Cox models, a 1-μg/ml increase in adiponectin was associated with a 3% (hazard ratio 1.03; 95% confidence interval 1.01 to 1.05; P = 0.02) increased risk for all-cause and 6% (hazard ratio 1.06; 95% confidence interval 1.03 to 1.09; P < 0.001) increased risk for cardiovascular mortality. High, rather than low, adiponectin is associated with increased mortality in this cohort of patients with chronic kidney disease stages 3 to 4. Further studies are necessary to confirm this association and to elucidate the underlying mechanisms.
- 1 September 2006
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 17 (9) , 2599-2606
Open AccessAdiponectin and Mortality in Patients with Chronic Kidney Disease
Adiponectin is presumed to possess antiatherogenic and cardioprotective properties. Limited data exist on the relationship between adiponectin and mortality in the earlier stages of chronic kidney disease. The Modification of Diet in Renal Disease study was a randomized, controlled trial that was conducted between 1989 and 1993. Adiponectin was measured in frozen samples that were obtained at baseline (N = 820). Survival status and cause of death, up to December 31, 2000, were obtained from the National Death Index. Multivariable Cox models were used to examine the relationship of adiponectin with all-cause and cardiovascular mortality. Mean ± SD age was 52 ± 12 yr, and mean ± SD glomerular filtration rate (GFR) rate was 33 ± 12 ml/min per 1.73 m2. Eighty-five percent of participants were white, and 60% were male. Mean ± SD adiponectin was 12.8 ± 8.0 μg/ml. Triglycerides, insulin resistance, glucose, body mass index, GFR, C-reactive protein, and albumin were inversely related and proteinuria and HDL cholesterol were directly related to adiponectin. During the 10-year follow-up period, 201 (25%) participants died of any cause, and 122 (15%) from cardiovascular disease. In multivariable adjusted Cox models, a 1-μg/ml increase in adiponectin was associated with a 3% (hazard ratio 1.03; 95% confidence interval 1.01 to 1.05; P = 0.02) increased risk for all-cause and 6% (hazard ratio 1.06; 95% confidence interval 1.03 to 1.09; P < 0.001) increased risk for cardiovascular mortality. High, rather than low, adiponectin is associated with increased mortality in this cohort of patients with chronic kidney disease stages 3 to 4. Further studies are necessary to confirm this association and to elucidate the underlying mechanisms.